Efficacy of taxane-based regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer.

Chang Jiang,Liang-Ping Xia,Chen-Xi Yin,Gui-Fang Guo,Wen-Zhuo He,Xu-Xian Chen,Fang-Xin Liao,Xiu-Yu Cai,Yu-Ming Rong,Qiong Yang,Bei Zhang,Hui-Juan Qiu

doi:10.7314/apjcp.2014.15.13.5493

Chang Jiang, Liang-Ping Xia + Show 10 more

Open Access

https://doi.org/10.7314/apjcp.2014.15.13.5493

Copy DOI

Abstract

To compare the efficacy of taxane-based regimens in the first line setting retrospectively in Chinese patients with recurrent and/or metastatic esophageal cancer. We analyzed 102 recurrent and/or metastatic esophageal cancer patients who received taxanes-based regimens in a first-line setting from January 2009 to December 2013. Sixteen (15.7%) patients were administered Nab-PTX based chemotherapy and 86 patients (84.3%) received paclitaxel (PTX) or docetaxel (DTX) based chemotherapy. Patients in the PTX/DTX group could be further divided into TP (71 patients) and TPF (15 patients) groups. The objective response rate (ORR) of all patients was 20.6%, and the disease control rate (DCR) was 67.6%. The median overall survival (OS) was 10.5 months (95% CI 10.1-16.4) and the median progression-free survival (PFS) was 6.04 months (95% CI 5.09-7.91). The DCR was higher in the TPF group than the TP group (93.3% vs. 59.1%; p = 0.015 ). There were no significant differences in ORR, OS, and PFS among Nab-PTX, TPF and TP groups. The three regimens of Nab-PTX based, TP and TPF proved active in a first line setting of Chinese patients with recurrent and/or metastatic esophageal cancer, and should thus be regarded as alternative treatments.

Highlights

Esophageal cancer is the eighth most common cancer with a dismal prognosis, which cause the sixth cancerrelated mortality worldwide (IARC, 2012)
The three regimens of Nab-PTX based, TP and TPF proved active in a first line setting of Chinese patients with recurrent and/or metastatic esophageal cancer, and should be regarded as alternative treatments
The studies to compare taxanes based regimens with PF regimen were not reported except Fujita Y et al (Fujita, et al, 2008), who reported no significant differences in median survival time between docetaxel plus nedaplatin and cisplatin plus 5-fluorouracil in esophageal cancer patients

Summary

Introduction

Esophageal cancer is the eighth most common cancer with a dismal prognosis, which cause the sixth cancerrelated mortality worldwide (IARC, 2012). Objective: To compare the efficacy of taxane-based regimens in the first line setting retrospectively in Chinese patients with recurrent and/or metastatic esophageal cancer.

Results

Conclusion